2017 Press Releases
|2017 | 2016 | 2015|
06/22/17Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation for Omaveloxolone for the Treatment of Friedreich’s Ataxia
06/01/17Reata Pharmaceuticals, Inc. Announces Positive Data From Part One of Moxie Trial of Omaveloxolone for Friedreich’s Ataxia
03/03/17Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2016 Financial and Operating Results
03/02/17Reata Pharmaceuticals, Inc. Announces the Retirement of Board Member Dennis Stone, M.D., and the Addition of New Board Member William D. McClellan, Jr.
02/23/17Reata Announces Initiation of Phase 2/3 Study of Bardoxolone Methyl in the Treatment of Chronic Kidney Disease Due to Alport Syndrome